PCSK9 and metabolic syndrome: With particular interest in dyslipidemia management, treatment with PCSK9 inhibitors to decrease levels of LDL-cholesterol was reported in 2016 to be too expensive and unaffordable by health systems [124] and in 2018, the American College of Cardiology guidelines concluded that the price of PCSK9 inhibitors must be reduced by almost 70% to meet cost-effectiveness standards [125]; although a more recent study has proven PCSK9 inhibitors to be cost-effective only at a substantially lower cost and in the very-high-risk population [126].